Sanofi $SNY Shares Sold by Hotchkis & Wiley Capital Management LLC

Key Points

• Hotchkis & Wiley Capital Management LLC reduced its holdings in Sanofi by 2.1%, owning approximately 0.09% of the company worth $122.57 million after selling 47,980 shares in the first quarter.
• Sanofi's stock has received positive ratings from multiple analysts, with a consensus target price of $62.00 and a majority rating of "Buy" or better.
• The company reported a net income of $0.90 earnings per share for the last quarter, missing expectations by $0.06 while revenues were significantly above analyst estimates at $11.34 billion.

Hotchkis & Wiley Capital Management LLC cut its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 2.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,209,996 shares of the company's stock after selling 47,980 shares during the quarter. Hotchkis & Wiley Capital Management LLC owned about 0.09% of Sanofi worth $122,566,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Sanofi by 124.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock worth $1,344,000 after acquiring an additional 13,358 shares during the period. Axxcess Wealth Management LLC raised its holdings in Sanofi by 130.5% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock valued at $568,000 after acquiring an additional 5,794 shares during the last quarter. Ballentine Partners LLC raised its holdings in Sanofi by 68.7% in the 1st quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock valued at $1,445,000 after acquiring an additional 10,617 shares during the last quarter. Sowell Financial Services LLC acquired a new stake in Sanofi in the 1st quarter valued at about $328,000. Finally, Farther Finance Advisors LLC raised its holdings in Sanofi by 66.2% in the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock valued at $338,000 after acquiring an additional 2,476 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on SNY. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research note on Monday, June 2nd. Barclays reissued an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Sanofi in a research note on Tuesday, August 5th. Finally, Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Three research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $62.00.

Sanofi Stock Down 0.4%

Sanofi stock traded down $0.19 during mid-day trading on Wednesday, reaching $50.11. 2,044,486 shares of the company's stock were exchanged, compared to its average volume of 2,544,232. The company has a market cap of $123.05 billion, a P/E ratio of 12.05, a P/E/G ratio of 1.19 and a beta of 0.48. Sanofi has a twelve month low of $44.73 and a twelve month high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The company has a fifty day moving average of $48.68 and a 200-day moving average of $51.67.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.Sanofi's quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.73 earnings per share. Sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.